Hematologic toxicity is rare in relapsed patients treated with belinostat: a systematic review of belinostat toxicity and safety in peripheral T-cell lymphomas

References

• SavageKJChhanabhaiMGascoyneRDConnorsJMCharacterization of peripheral T-cell lymphomas in a single North American institution by the WHO classificationAnn Oncol200415101467147515367405
   PubMed Web of Science ®Google Scholar
• MoskowitzAJLunningMAHorwitzSMHow I treat the peripheral T-cell lymphomasBlood2014123172636264424615779
   PubMed Web of Science ®Google Scholar
• VoseJArmitageJWeisenburgerDProject IT-CL, International T-Cell Lymphoma ProjectInternational peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomesJ Clin Oncol200826254124413018626005
   PubMed Web of Science ®Google Scholar
• FossardGBroussaisFCoelhoIRole of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centersAnn Oncol201829371572329253087
   PubMed Web of Science ®Google Scholar
• D’AmoreFRelanderTLauritzsenGFUp-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01J Clin Oncol201230253093309922851556
   PubMed Web of Science ®Google Scholar
• WilhelmMSmetakMReimerPFirst-line therapy of peripheral T-cell lymphoma: extension and long-term follow-up of a study investigating the role of autologous stem cell transplantationBlood Cancer J201667e45227471868
   PubMedGoogle Scholar
• MercadalSBrionesJXicoyBIntensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphomaAnn Oncol200819595896318303032
   PubMed Web of Science ®Google Scholar
• Kharfan-DabajaMAKumarAAyalaEClinical Practice Recommendations on Indication and Timing of Hematopoietic Cell Transplantation in Mature T Cell and NK/T Cell Lymphomas: An International Collaborative Effort on Behalf of the Guidelines Committee of the American Society for Blood and Marrow TransplantationBiol Blood Marrow Transplant201723111826183828797780
   PubMed Web of Science ®Google Scholar
• MakVHammJChhanabhaiMSurvival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivorsJ Clin Oncol201331161970197623610113
   PubMed Web of Science ®Google Scholar
• MckinneyMMoffittABGaulardPThe Genetic Basis of Hepatosplenic T-cell LymphomaCancer Discov20177436937928122867
   PubMed Web of Science ®Google Scholar
• YooHYSungMKLeeSHA recurrent inactivating mutation in RHOA GTPase in angioimmunoblastic T cell lymphomaNat Genet201446437137524584070
   PubMed Web of Science ®Google Scholar
• OdejideOWeigertOLaneAAA targeted mutational landscape of angioimmunoblastic T-cell lymphomaBlood201412391293129624345752
   PubMed Web of Science ®Google Scholar
• CrescenzoRAbateFLasorsaEConvergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphomaCancer Cell201527451653225873174
   PubMed Web of Science ®Google Scholar
• van ArnamJSLimMSElenitoba-JohnsonKSJNovel insights into the pathogenesis of T-cell lymphomasBlood2018131212320233029666117
   PubMed Web of Science ®Google Scholar
• da Silva AlmeidaACAbateFKhiabanianHThe mutational landscape of cutaneous T cell lymphoma and Sézary syndromeNat Genet201547121465147026551667
   PubMed Web of Science ®Google Scholar
• DobashiATsuyamaNAsakaRFrequent BCOR aberrations in extranodal NK/T-cell lymphoma, nasal typeGenes Chromosomes Cancer201655546047126773734
   PubMed Web of Science ®Google Scholar
• QuKZabaLCSatpathyATChromatin Accessibility Landscape of Cutaneous T Cell Lymphoma and Dynamic Response to HDAC InhibitorsCancer Cell2017321e242741
   Web of Science ®Google Scholar
• PiekarzRLFryeRPrinceHMPhase 2 trial of romidepsin in patients with peripheral T-cell lymphomaBlood2011117225827583421355097
   PubMed Web of Science ®Google Scholar
• SteeleNLPlumbJAVidalLA phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumorsClin Cancer Res200814380481018245542
   PubMed Web of Science ®Google Scholar
• GimsingPHansenMKnudsenLMA phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasiaEur J Haematol200881317017618510700
   PubMed Web of Science ®Google Scholar
• FossFAdvaniRDuvicMA Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphomaBr J Haematol2015168681181925404094
   PubMed Web of Science ®Google Scholar
• O’ConnorOAHorwitzSMassziTBelinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) StudyJ Clin Oncol201533232492249926101246
   PubMed Web of Science ®Google Scholar
• ReimerPChawlaSLong-term complete remission with belinostat in a patient with chemotherapy refractory peripheral T-cell lymphomaJ Hematol Oncol201366924020452
   PubMed Web of Science ®Google Scholar
• SteeleNLPlumbJAVidalLPharmacokinetic and pharmacodynamic properties of an oral formulation of the histone deacetylase inhibitor Belinostat (PXD101)Cancer Chemother Pharmacol20116761273127920706839
   PubMed Web of Science ®Google Scholar
• MackayHJHirteHColganTPhase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumoursEur J Cancer20104691573157920304628
   PubMed Web of Science ®Google Scholar
• ZainJMFossFMDiefenbachCSPreliminary Results of An Ongoing Phase I Trial of Oral Belinostat a Novel Histone Deacetylase Inhibitor in Patients with Lymphoid MalignanciesBlood2011118213710
   Web of Science ®Google Scholar
• GiacconeGRajanABermanAPhase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumorsJ Clin Oncol201129152052205921502553
   PubMed Web of Science ®Google Scholar
• RamalingamSSBelaniCPRuelCPhase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesotheliomaJ Thorac Oncol2009419710119096314
   PubMed Web of Science ®Google Scholar
• YeoWChungHCChanSLEpigenetic therapy using belinostat for patients with unresectable hepatocellular carcinoma: a multicenter phase I/II study with biomarker and pharmacokinetic analysis of tumors from patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research GroupJ Clin Oncol201230273361336722915658
   PubMed Web of Science ®Google Scholar
• CashenAJuckettMJumonvilleAPhase II study of the histone deacetylase inhibitor belinostat (PXD101) for the treatment of myelodysplastic syndrome (MDS)Ann Hematol2012911333821538061
   PubMed Web of Science ®Google Scholar
• KirschbaumMHFoonKAFrankelPA phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: a California Cancer Consortium StudyLeuk Lymphoma201455102301230424369094
   PubMed Web of Science ®Google Scholar
• PuvvadaSDGuillén-RodríguezJMRiveraXIA Phase II Exploratory Study of PXD-101 (Belinostat) Followed by Zevalin in Patients with Relapsed Aggressive High-Risk LymphomaOncology201793640140528869931
   PubMed Web of Science ®Google Scholar
• AgarwalNMcphersonJPBaileyHA phase I clinical trial of the effect of belinostat on the pharmacokinetics and pharmacodynamics of warfarinCancer Chemother Pharmacol201677229930826719074
   PubMed Web of Science ®Google Scholar
• PuvvadaSDLiHRimszaLMA phase II study of belinostat (PXD101) in relapsed and refractory aggressive B-cell lymphomas: SWOG S0520Leuk Lymphoma201657102359236926758422
   PubMed Web of Science ®Google Scholar
• GoeyAKFiggWDUGT genotyping in belinostat dosingPharmacol Res2016105222726773202
   PubMed Web of Science ®Google Scholar
• CoiffierBProBPrinceHMResults from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapyJ Clin Oncol201230663163622271479
   PubMed Web of Science ®Google Scholar
• O’ConnorOAHorwitzSHamlinPPhase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignanciesJ Clin Oncol200927264357436419652067
   PubMed Web of Science ®Google Scholar
• HorwitzSMAdvaniRHBartlettNLObjective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotinBlood2014123203095310024652992
   PubMed Web of Science ®Google Scholar
• ProBAdvaniRBricePBrentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II studyJ Clin Oncol201230182190219622614995
   PubMed Web of Science ®Google Scholar
• DupuisJMorschhauserFGhesquièresHCombination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: a non-randomised, phase 1b/2 studyLancet Haematol201524e160e16526687958
   PubMed Web of Science ®Google Scholar
• JohnstonPBCashenAFNikolinakosPGSafe and Effective Treatment of Patients with Peripheral T-Cell Lymphoma (PTCL) with the Novel HDAC Inhibitor, Belinostat, in Combination with CHOP: Results of the Bel-CHOP Phase 1 TrialBlood201512623253
   Web of Science ®Google Scholar
• BrunerDWMovsasBBaschECapturing the patient perspective: patient-reported outcomes as clinical trial endpointsAm Soc Clin Oncol Educ Book201213914424451723
   PubMedGoogle Scholar
• DueckACMendozaTRMitchellSAValidity and Reliability of the US National Cancer Institute’s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)JAMA Oncol2015181051105926270597
   PubMed Web of Science ®Google Scholar
• BaschEDueckACRogakLJFeasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical TrialsJAMA Oncol2017381043105028208174
   PubMed Web of Science ®Google Scholar
• HussonOJonesRLQ-TWiST: what really matters to the cancer patient?Cancer2017123122200220228294292
   PubMed Web of Science ®Google Scholar